Michael G Donovan

US Patent:

6359194, Mar 19, 2002

Filed:

Apr 8, 1999

Appl. No.:

09/288292

Inventors:

Katherine Galvin - Cambridge MA
Dean A. Falb - Wellesley MA
Michael J. Donovan - Brookline MA
Dennis Huszar - Acton MA

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
Brigham Womens Hospital - Boston MA

International Classification:

A01K 67027

US Classification:

800 18, 800 3, 800 8, 800 13, 800 21, 800 25, 536 231, 536 235, 4353201, 435325, 435455

Abstract:

The present invention is based on the generation and phenotypic characterization of transgenic knockout homozygous rchd534 mutant mice which display characteristic cardiovascular disease symptoms. Such transgenic knockout homozygous rchd534 mutant mice are useful models for the analysis and characterization of rchd534 protein involvement in development and homeostasis of the cardiovascular system and tissue-specific regulation of the TGF- signaling pathways. Such transgenic mice may be used for screening compounds that may potentially useful for treating or preventing cardiovascular disease.

US Patent:

7983396, Jul 19, 2011

Filed:

May 15, 2008

Appl. No.:

12/121515

Inventors:

William Bertozzi - Lexington MA, US
Michael Donovan - Dover MA, US
Alexei Klimenko - Tyngsboro MA, US
Stephen E. Korbly - Acton MA, US
William Park - Somerville MA, US

Assignee:

Passport Systems, Inc. - Billerica MA

International Classification:

H01J 35/18
H01J 35/10

US Classification:

378141, 378119

Abstract:

Methods and systems for generating bremsstrahlung with enhanced photon flux in a narrow cone at forward angles utilize a thin target of a high-Z material such as gold as radiator, supported on a tube of a low-Z material such as titanium, which tube contains a circulating fluid such as water which acts as a coolant and also may absorb the incident electron beam.

US Patent:

8340251, Dec 25, 2012

Filed:

Jun 13, 2011

Appl. No.:

13/158851

Inventors:

William Bertozzi - Lexington MA, US
Michael Donovan - Dover MA, US
Alexei Klimenko - Tyngsboro MA, US
Stephen E. Korbly - Acton MA, US
William Park - Somerville MA, US

Assignee:

Passport Systems, Inc. - Billerica MA

International Classification:

H01J 35/18
H01J 35/10

US Classification:

378141, 378119

Abstract:

Methods and systems for generating bremsstrahlung with enhanced photon flux in a narrow cone at forward angles utilize a thin target of a high-Z material such as gold as radiator, supported on a tube of a low-Z material such as titanium, which tube contains a circulating fluid such as water which acts as a coolant and also may absorb the incident electron beam.

US Patent:

20030097668, May 22, 2003

Filed:

Feb 8, 2002

Appl. No.:

10/067741

Inventors:

Katherine Galvin - Cambridge MA, US
Dean Falb - Wellesley MA, US
Michael Donovan - Brookline MA, US
Dennis Huszar - Acton MA, US
Michael Gimbrone - Jamaica Plain MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A01K067/027
C12N005/06

US Classification:

800/009000, 800/018000, 435/354000

Abstract:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, advanced atherosclerosis/plaque rupture, ischemia/reperfusion, hypertension, restenosis, cardiac calcification, allo/xenograft valvular calcifications, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. Moreover, the present invention is further based in part on the generation and phenotypic characterization of transgenic knockout homozygous rchd534 mutant mice which display characteristic cardiovascular disease symptoms. Such transgenic knockout homozygous rchd534 mutant mice are useful models for the analysis and characterization of rchd534 protein involvement in development and homeostasis of the cardiovascular system and tissue-specific regulation of the TGF- signaling pathways.

US Patent:

20100177950, Jul 15, 2010

Filed:

Jul 27, 2009

Appl. No.:

12/462041

Inventors:

Michael Donovan - Cambridge MA, US
Faisal Khan - Fishkill NY, US
Gerardo Fernandez - Yorktown Heights NY, US
Ali Tabesh - New York NY, US
Ricardo Mesa-Tejada - Pleasantville NY, US
Carlos Cordon-Cardo - New York NY, US
Jose Costa - Guilford CT, US
Stephen Fogarasi - Pawling NY, US
Yevgen Vengrenyuk - Mamaroneck NY, US

Assignee:

Aureon Laboratories, Inc. - Yonkers NY

International Classification:

G06K 9/00
G06F 19/00

US Classification:

382133, 702 19

Abstract:

Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts risk of prostate cancer progression in a patient, where the model is based on features including one or more (e.g., all) of preoperative PSA, dominant Gleason Grade, Gleason Score, at least one of a measurement of expression of AR in epithelial and stromal nuclei and a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of average edge length in the minimum spanning tree (MST) of epithelial nuclei, and a morphometric measurement of area of non-lumen associated epithelial cells relative to total tumor area. In some embodiments, the morphometric information is based on image analysis of tissue subject to multiplex immunofluorescence and may include characteristic(s) of a minimum spanning tree (MST) and/or a fractal dimension observed in the images.

US Patent:

20100184093, Jul 22, 2010

Filed:

Aug 28, 2009

Appl. No.:

12/584048

Inventors:

Michael Donovan - Cambridge MA, US
Faisal Khan - Fishkill NY, US
Jason Alter - Stamford CT, US
Gerardo Fernandez - Yorktown Heights NY, US
Ricardo Mesa-Tejada - Pleasantville NY, US
Douglas Powell - Bronxville NY, US
Valentina Bayer Zubek - Yonkers NY, US
Stefan Hamann - New Rochelle NY, US
Carlos Cordon-Cardo - New York NY, US
Jose Costa - Guilford CT, US

Assignee:

Aureon Laboratories, Inc. - Yonkers NY

International Classification:

G01N 33/53
C12M 1/34

US Classification:

435 721, 4352871

Abstract:

Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts whether a patient is likely to have a favorable pathological stage of prostate cancer, where the model is based on features including one or more (e.g., all) of preoperative PSA, Gleason Score, a measurement of expression of androgen receptor (AR) in epithelial and stromal nuclei and/or a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of a ratio of area of epithelial nuclei outside gland units to area of epithelial nuclei within gland units, and a morphometric measurement of area of epithelial nuclei distributed away from gland units. In some embodiments, quantitative measurements of protein expression in cell lines are utilized to objectively assess assay (e.g., multiplex immunofluorescence (IF)) performance and/or to normalize features for use within a predictive model.

US Patent:

20130080134, Mar 28, 2013

Filed:

Jun 4, 2012

Appl. No.:

13/488176

Inventors:

Michael Donovan - Newton MA, US
Faisal Khan - Fishkill NY, US
Jason Alter - Carlsbad CA, US
Gerardo Fernandez - San Jose CA, US
Ricardo Mesa-Tejada - Pleasantville NY, US
Douglas Powell - Gettysburg PA, US
Valentina Bayer Zubek - Yonkers NY, US
Stefan Hamann - Cambridge MA, US
Jose Costa - Guilford CT, US

Assignee:

Fundação D. Anna Sommer Champalimaud e Dr. Carlos Montez Champalimaud - Lisboa

International Classification:

G06F 19/00

US Classification:

703 11

Abstract:

In general, one aspect of the subject matter described in this specification can be embodied in methods for assessing risk associated with prostate cancer, the methods including the actions of receiving patient data, comparing, with a processor executing code, the patient data to one or more predictive models, the one or more predictive models comprising at least one of (a) a disease progression (DP) model, the DP model being configured to predicts a likelihood of developing significant disease progression, and (b) a favorable pathology (FP) model, the FP model being configured to predict a likelihood of having organ confined, low grade disease in a prostatectomy, and outputting one or more results of the comparison Other embodiments of the various aspects include corresponding systems, apparatus, and computer program products.